ALKS
Alkermes plc

2,169
Mkt Cap
$4.73B
Volume
2.03M
52W High
$36.45
52W Low
$25.17
PE Ratio
14.24
ALKS Fundamentals
Price
$28.78
Prev Close
$28.00
Open
$28.01
50D MA
$29.44
Beta
0.57
Avg. Volume
1.64M
EPS (Annual)
$2.17
P/B
2.74
Rev/Employee
$865,351.11
Loading...
Loading...
News
all
press releases
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1...
Business Wire·18h ago
News Placeholder
More News
News Placeholder
Alkermes (NASDAQ:ALKS) EVP Sells 4,000 Shares
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 4,000 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $28.00...
MarketBeat·4d ago
News Placeholder
Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 4,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $28.00, for a total...
MarketBeat·4d ago
News Placeholder
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.04 Million in Alkermes plc $ALKS
VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Alkermes plc (NASDAQ:ALKS - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·7d ago
News Placeholder
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The...
Business Wire·7d ago
News Placeholder
Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC decreased its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 8.7% during the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·11d ago
News Placeholder
Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS
Pacer Advisors Inc. trimmed its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 10.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·11d ago
News Placeholder
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Alkermes plc (NASDAQ:ALKS - Get Free Report) have received an average rating of "Moderate Buy" from the sixteen research firms that are covering the stock, Marketbeat.com reports. Three...
MarketBeat·17d ago
News Placeholder
Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS
Frazier Life Sciences Management L.P. lifted its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 66.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·24d ago
News Placeholder
EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS
EcoR1 Capital LLC purchased a new stake in Alkermes plc (NASDAQ:ALKS - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 500,000 shares of the...
MarketBeat·25d ago
<
1
2
...
>

Latest ALKS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.